Article (Scientific journals)
Receptor Density Influences the Recruitment Bias of Aripiprazole and Brexpiprazole at the Dopamine D2L Receptor.
Ferraiolo, Mattia; Ponthot, Romane; Atik, Hicham et al.
2022In Fundamental and Clinical Pharmacology
Peer Reviewed verified by ORBi
 

Files


Full Text
Article_Ferraiolo et al_Receptor density and bias D2L_2022.pdf
Publisher postprint (1.6 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Dopamine; antipsychotics; functional selectivity; receptor density; schizophrenia; signaling bias; Pharmacology (medical); Pharmacology
Abstract :
[en] Aripiprazole, brexpiprazole and cariprazine are dopamine D2 receptor ligands considered as effective and tolerable antipsychotics. Brain imaging studies showed that schizophrenia is characterized by elevated dopamine receptor density, which is exacerbated by antipsychotic treatments. Despite the complexity of translating in vitro studies to human neurobiology, overexpression experiments in transfected cells provide a proof-of-concept model of the influence of receptor density on antipsychotic treatments. Since receptor density was demonstrated to influence the signaling profile of dopaminergic ligands, we hypothesized that high dopamine D2 receptor expression levels could influence the recruitment of Gi1 and β-arrestin2 in response to partial agonists used as antipsychotics. A nanoluciferase complementation assay was used to monitor β-arrestin2 and Gi1 recruitment at the dopamine D2L receptor in response to aripiprazole, brexpiprazole and cariprazine. This was performed in transfected cells carrying a doxycycline-inducible system allowing to manipulate the expression of the dopamine D2L receptors. Increasing D2L receptor density reoriented aripiprazole's preferential recruitment from Gi1 to β-arrestin2. With respect to brexpiprazole, which showed inverse agonism for β-arrestin2 recruitment at the lower receptor density tested, inverse agonism for Gi1 recruitment was observed when tested at a high receptor expression level. At variance, cariprazine evoked a potent partial agonism for β-arrestin2 recruitment only, in all the tested conditions. D2L receptor density appears to shape the recruitment bias of aripiprazole and brexpiprazole, but not cariprazine. This suggests that changes in receptor expression level could qualitatively influence the functional response of partial agonists used in psychiatry.
Disciplines :
Biochemistry, biophysics & molecular biology
Pharmacy, pharmacology & toxicology
Author, co-author :
Ferraiolo, Mattia ;  Neuropharmacology Laboratory - Institute of Neurosciences - UCLouvain, Brussels, Belgium
Ponthot, Romane;  Neuropharmacology Laboratory - Institute of Neurosciences - UCLouvain, Brussels, Belgium
Atik, Hicham;  Neuropharmacology Laboratory - Institute of Neurosciences - UCLouvain, Brussels, Belgium
Koener, Beryl;  Neuropharmacology Laboratory - Institute of Neurosciences - UCLouvain, Brussels, Belgium
Hanson, Julien  ;  Université de Liège - ULiège > GIGA > GIGA Molecular Biology of Diseases - Molecular Pharmacology
Hermans, Emmanuel;  Neuropharmacology Laboratory - Institute of Neurosciences - UCLouvain, Brussels, Belgium
Language :
English
Title :
Receptor Density Influences the Recruitment Bias of Aripiprazole and Brexpiprazole at the Dopamine D2L Receptor.
Publication date :
29 June 2022
Journal title :
Fundamental and Clinical Pharmacology
ISSN :
0767-3981
eISSN :
1472-8206
Publisher :
Wiley, England
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 04 July 2022

Statistics


Number of views
55 (3 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
1
Scopus citations®
without self-citations
0
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi